Vir Biotechnology Inc V.VIR

Primary Symbol: VIR

Healthcare Biotechnology

Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.

NDAQ:VIR - Post by User

Vir Biotechnology Inc > .11 cents , last chance to load up on giveaway shares

<< Previous

Bullboard Posts

Next >>

Comment by Redearth7on Jul 28, 2020 3:15pm

75 Views

Post# 31332785

RE:RE:.11 cents , last chance to load up on giveaway shares

NEW CHAIRMAN OF THE BOARD...S/B WORTH A COUPLE MILLION FREE SHARES...TRYING TO BE FUNNY...NOT.

Maybe his (mr.chairman) options should be priced at .80 cents like all the others that were taken advantage of, stll looks like a dog, acts like a dog so it must be a DOG.

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments